Drug
LN 145 LN 144
LN 145 LN 144: highest development phase Phase 1, developed by Iovance Biotherapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Iovance Biotherapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| LN-145/LN-144 NCT06566092 | Phase 1 | Soft Tissue Sarcoma |
Latest
No recent events.
Follow LN 145 LN 144 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.